Matthew Sykes
Stock Analyst at Goldman Sachs
(4.07)
# 547
Out of 5,124 analysts
210
Total ratings
54.42%
Success rate
11.05%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $17.25 | -71.01% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $5.05 | -40.59% | 14 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $16.31 | -60.15% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $47.11 | -4.48% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $6.15 | +30.08% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $31.72 | +51.32% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $17.64 | -3.63% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $182.22 | -12.19% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $11.76 | -14.97% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $96.75 | +29.20% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $11.46 | +22.16% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $228.92 | +4.84% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $18.84 | +38.00% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $199.48 | -14.78% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $102.14 | -45.17% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $130.06 | -38.49% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.87 | -19.79% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $229.09 | -17.06% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $1.95 | -10.26% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $3.25 | +30.77% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $42.10 | -12.11% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $101.56 | -36.00% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $225.41 | +10.91% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $6.36 | +277.36% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,394.19 | -6.76% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $8.31 | +44.40% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $579.45 | +10.45% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $136.07 | +6.56% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $44.97 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $17.25
Upside: -71.01%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $5.05
Upside: -40.59%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $16.31
Upside: -60.15%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $47.11
Upside: -4.48%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $6.15
Upside: +30.08%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $31.72
Upside: +51.32%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $17.64
Upside: -3.63%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $182.22
Upside: -12.19%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $11.76
Upside: -14.97%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $96.75
Upside: +29.20%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $11.46
Upside: +22.16%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $228.92
Upside: +4.84%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $18.84
Upside: +38.00%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $199.48
Upside: -14.78%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $102.14
Upside: -45.17%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $130.06
Upside: -38.49%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.87
Upside: -19.79%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $229.09
Upside: -17.06%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $1.95
Upside: -10.26%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $3.25
Upside: +30.77%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $42.10
Upside: -12.11%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $101.56
Upside: -36.00%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $225.41
Upside: +10.91%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $6.36
Upside: +277.36%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,394.19
Upside: -6.76%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $8.31
Upside: +44.40%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $579.45
Upside: +10.45%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $136.07
Upside: +6.56%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $44.97
Upside: -